FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
haura nar raananaa	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Scibetta James S						2. Issuer Name and Ticker or Trading Symbol Pacira Pharmaceuticals, Inc. [PCRX]									Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Scibella James S						- asa								-	Director			10% O	wner	
(Last)		3. Date of Earliest Transaction (Month/Day/Year) 12/30/2013									X Office below	r (give title)		Other (below)	specify					
C/O PAG	CIRA PHAF	RMACEUTICAL											Chief Financial Officer							
	AN WAY, S																			
	III WAI, C		4. If A	If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)																X Form filed by One Reporting Person				
PARSIP	PANY N.	J (07054												Form filed by More than One Reporting Person					
(City)	(S	tate) (Zip)																	
		Tab	le I - N	lon-Deriv	ative	Sec	urit	ies Ac	quired,	Dis	posed o	of, or	Bene	ficial	ly Owne	d				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						Exec if an	Deemed cution Date, ny nth/Day/Year)		Transaction Dispo			curities Acquired (A osed Of (D) (Instr. 3 i)			Securit Benefic Owned	ties F cially (I		n: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership	
						Code	v	Amount	(A) or)	Price	Follow Report Transa (Instr. 3	ed		tr. 4)	(Instr. 4)				
Common Stock 12/30/2						013			М		10,000 A		A	\$1.6	1 15	5,000		D		
Common Stock 12/30/2				013		S ⁽¹⁾		10,000		D	\$55.5	5 5	5,000		D					
		T	able II	- Deriva					uired, D						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	r) if any		4. Transaction Code (Instr. 8)				6. Date Ex Expiration (Month/Da	е	nd 7. Title and Amount of Securities Underlying Derivative Security (Instr.		r. 3	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owner Form: Direct or Ind (I) (Ins 4)	Ownership Form: Direct (D) or Indirect (I) (Instr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	or Nu of	mber ares						
Employee Stock Option (right to buy)	\$1.61	12/30/2013			M			10,000	(2)	0	9/02/2020	Commo	ⁿ 10	,000	\$0	32,989		D		

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- 2. The option vested as to 25% of the options on September 2, 2011 and vests as to the remaining options in successive equal monthly installments for the subsequent 36 months. The options became exercisable, to the extent vested, from and after the Issuer's initial public offering.

/s/ James Scibetta 01/02/2014

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.